New vaccine aims to train immune system against lung cancer
NCT ID NCT01720836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1/2 trial is testing a vaccine made from a piece of the MUC1 protein, which is found on many lung cancer cells. The vaccine is mixed with an adjuvant called Poly-ICLC to boost the immune response. Thirty patients with early or locally advanced non-small cell lung cancer will receive the vaccine every three weeks for three doses, with optional yearly boosters. The goal is to see if the vaccine triggers the body to produce antibodies against MUC1, potentially helping the immune system fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MUC1 peptide vaccine with Poly-ICLC (Hiltonol) adjuvant
What this could lead to
If successful, this vaccine could train the immune system to recognize and attack lung cancer cells, potentially preventing recurrence in early-stage patients.
What could go wrong
This is an early phase 1/2 trial with only 30 participants, so it is too small to prove effectiveness. The vaccine may not produce a strong enough immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States